TORAFIC study protocol: torasemide prolonged release versus furosemide in patients with chronic heart failure

References

• Mosterd A, Hoes AW, de Bruyne MC et al. Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. Eur. Heart J.20, 447–455 (1999).
   PubMed Web of Science ®Google Scholar
• Anguita Sánchez M, Crespo Leiro MG, de Teresa Galván E et al; PRICE study investigators. Prevalence of heart failure in the Spanish general population aged over 45 years. Rev. Esp. Cardiol.61, 1041–1049 (2008).
   PubMed Web of Science ®Google Scholar
• McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N. Engl. J. Med.285, 1441–1446 (1971).
   PubMed Web of Science ®Google Scholar
• Cleland JG, Gemmell I, Khand A, Boddy A. Is the prognosis of heart failure improving? Eur. Heart J.1, 229–241 (1999).
   Web of Science ®Google Scholar
• Cleland JG, Khand A, Clark A. The heart failure epidemic: exactly how big is it? Eur. Heart J.22, 623–626 (2001).
   PubMed Web of Science ®Google Scholar
• Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation111, 2837–2849 (2005).
   PubMed Web of Science ®Google Scholar
• Burlew BS, Weber KT. Connective tissue and the heart. Functional significance and regulatory mechanisms. Cardiol. Clin.18, 435–442 (2000).
   PubMedGoogle Scholar
• Chapman RE, Spinale FG. Extracellular protease activation and unraveling of the myocardial interstitium: critical steps toward clinical applications. Am. J. Physiol. Heart Circ. Physiol.286, H1–H10 (2004).
   Google Scholar
• Burlew BS, Weber KT. Cardiac fibrosis as a cause of diastolic dysfunction. Herz27, 92–98 (2002).
   PubMed Web of Science ®Google Scholar
• Brower GL, Gardner JD, Forman MF et al. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur. J. Cardiothorac. Surg.30, 604–610 (2006).
   PubMed Web of Science ®Google Scholar
• Díez J, González A, López B, Querejeta R. Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. Nat. Clin. Pract. Cardiovasc. Med.2, 209–216 (2005).
   PubMedGoogle Scholar
• Querejeta R, Varo N, López B et al. Serum carboxy-terminal propeptide procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation101, 1729–1735 (2000).
   PubMed Web of Science ®Google Scholar
• Querejeta R, López B, González A et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation110, 1263–1268 (2004).
   PubMed Web of Science ®Google Scholar
• López B, Querejeta R, Varo N et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation104, 286–291 (2001).
   PubMed Web of Science ®Google Scholar
• González A, López B, Ravassa S et al. Biochemical markers of myocardial remodelling in hypertensive heart disease. Cardiovasc. Res.81, 509–518 (2009).
   PubMed Web of Science ®Google Scholar
• Swedberg K, Cleland J, Dargie H et al; Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur. Heart J.26, 1115–1140 (2005).
   PubMed Web of Science ®Google Scholar
• Hunt SA, Abraham WT, Chin MH et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation112, E154–E235 (2005).
   PubMed Web of Science ®Google Scholar
• Ishido H, Senzaki H. Torasemide for the treatment of heart failure. Cardiovasc. Hematol. Disord. Drug Targets8, 127–132 (2008).
   PubMedGoogle Scholar
• Cosín J, Díez J; TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur. J. Heart Fail.4, 507–513 (2002).
   PubMed Web of Science ®Google Scholar
• Dunn CJ, Fitton A, Brogden RN. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs49, 121–142 (1995).
   PubMed Web of Science ®Google Scholar
• Knauf H, Mutschler E. Clinical pharmacokinetics and pharmacodynamics of torasemide. Clin. Pharmacokinet.34, 1–24 (1998).
   PubMed Web of Science ®Google Scholar
• Dodion L, Ambroes Y, Lameire N. A comparison of the pharmacokinetics and diuretic effects of two loop diuretics, torasemide and furosemide, in normal volunteers. Eur. J. Clin. Pharmacol.31, 21–27 (1986).
   PubMed Web of Science ®Google Scholar
• Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin. Pharmacol. Ther.57, 601–609 (1995).
   PubMed Web of Science ®Google Scholar
• Barbanoj MJ, Ballester MR, Antonijoan RM et al. A bioavailability/bioequivalence and pharmacokinetic study of two oral doses of torasemide (5 mg and 10 mg): prolonged-release versus the conventional formulation. Clin. Exp. Pharmacol. Physiol.36(5–6), 469–477 (2008).
   PubMed Web of Science ®Google Scholar
• Gropper S, Rojas MJ, Guglietta A et al. Single and repeated-dose, randomized, cross-over, bioavailability clinical trial of torasemide immediate release compared to a new prolonged release formulation of torasemide. Basic Clin. Pharmacol. Toxicol.99(Suppl. 1), 48 (2006) (Abstract).
   Google Scholar
• Sutril Neo (torasemide prolonged release), summary of product characteristics. Ferrer Grupo, Barcelona, Spain (2006).
   Google Scholar
• Roca-Cusachs A, Aracil-Vilar J, Calvo-Gómez C et al.; the Torasemide-PR in Hypertension Clinical Trial Investigators Group. Clinical effects of torasemide prolonged release in milt to moderate hypertension: a randomized non-inferiority trial versus torasemide immediate release. Cardiovasc. Ther.26, 91–100 (2008).
   PubMed Web of Science ®Google Scholar
• Veeraveedu PT, Watanabe K, Ma M et al. Comparative effects of torasemide and furosemide in rats with heart failure. Biochem. Pharmacol.75, 649–659 (2008).
   PubMed Web of Science ®Google Scholar
• Veeraveedu PT, Watanabe K, Ma M et al. Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy. Eur. J. Pharmacol.581, 121–131 (2008).
   PubMed Web of Science ®Google Scholar
• López B, Querejeta R, González A, Sánchez E, Larman M, Díez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J. Am. Coll. Cardiol.43, 2028–2035 (2004).
   PubMed Web of Science ®Google Scholar
• López B, González A, Beaumont J, Querejeta R, Larman M, Díez J. Identification of a potential antifibrotic mechanism of torasemide in patients with chronic heart failure. J. Am. Coll. Cardiol.50, 859–867 (2007).
   PubMed Web of Science ®Google Scholar
• López B, Querejeta R, González A, Beaumont J, Larman M, Díez J. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension53(2), 236–242 (2009).
   PubMed Web of Science ®Google Scholar
• Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure Questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Am. Heart J.124, 1017–1025 (1992).
   PubMed Web of Science ®Google Scholar
• Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press.1, 113–119 (1992).
   PubMedGoogle Scholar
• Paulus WJ, Tschöpe C, Sanderson JE et al. How to diagnose diastolic heart failure: a consensus statement of the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur. Heart J.28, 2539–2550 (2007).
   PubMed Web of Science ®Google Scholar
• European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens.21, 1011–1053 (2003).
   PubMed Web of Science ®Google Scholar
• Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin. Pharmacol. Ther.21, 247–254 (1977).
   PubMed Web of Science ®Google Scholar
• González A, López B, Díez J. New directions in the assessment and treatment of hypertensive heart disease. Curr. Opin. Nephrol. Hypertens.14, 428–434 (2005).
   PubMed Web of Science ®Google Scholar